Citi opens 'upside 90-day catalyst watch' on Stryker
Citi opened an “upside 90-day catalyst watch” on shares of Stryker (SYK) while keeping a Buy rating on the name with a $420 price target The firm believes fundamentals in the U.S. medical technology sector remain “healthy” despite the recent volatility. Stryker has reported consistent double-digit revenue and earnings growth, the analyst tells investors in a research note.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Read More on SYK:
- Stryker announces launch of SmartHospital Platform
- Stryker price target raised to $400 from $386 at UBS
- Walmart downgraded, Etsy upgraded: Wall Street’s top analyst calls
- Stryker initiated with an Outperform at William Blair
- Stryker: Expanding Breast Reconstruction Leadership Warrants Premium Valuation and Buy Rating
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Kinder Morgan’s Expansion Upstream: Will It Transform the Untapped Backlog into a Major Breakthrough?
ENAVATE's Zenas Bio Pharma addition is just a side note — The main focus should be on the Obexelimab pipeline
3 Compelling Reasons Taiwan Semiconductor Stands Out as the Top AI Investment Choice
Trending news
MoreCrypto prices
More
